Secondary hyperparathyroidism (SHPT) is a severe, frequent, and progressive consequence of Chronic Kidney Disease (CKD) that is characterized by high concentrations of parathyroid hormone, mineral metabolic problems, and hypertrophy of the parathyroid gland. Since failing kidneys are unable to transform Vitamin A to its organic metabolite due to insufficient phosphate excretion, the body produces insoluble calcium phosphate, culminating in secondary hyperparathyroidism. Bone and joint pain, as well as limb abnormalities, are typical indications and symptoms of the illness. Patients with secondary hyperparathyroidism may experience poor quality of life and have a shorter life expectancy as a result of the disruptions they experience. SHPT is treated with a surgical procedure or the use of prescription medications that assist to keep the levels of parathyroid hormone, calcium, and phosphorous within the acceptable target ranges. Diabetes and hypertension, according to the National Institute of Diabetes and Digestive and Renal Diseases, are the two leading causes of chronic kidney disease. Patients with CKD, which can be caused by a variety of factors, can develop permanent kidney failure if left untreated.
Get Sample Report With Covid-19 impact analysis: https://www.coherentmarketinsights.com/insight/request-sample/1570
One of the key factors driving the global secondary hyperparathyroidism treatment market is the increasing frequency of chronic renal disease. According to the Centers for Disease Control and Prevention (CDC), 30 million people, or 15% of all adults in the United States, have chronic renal disease, of which 48 percent have significantly decreased kidney function. However, many people remain unaware of this condition. Furthermore, according to the National Kidney Foundation, chronic kidney disease affects 10% of the world’s population in 2016. Further, considerable research in the field of nephrology to develop novel medicines and therapies for the treatment of secondary hyperparathyroidism is fuelling the global secondary hyperparathyroidism treatment market expansion. Sanofi SA’s Hectorol capsules are now conducting Phase 3 clinical studies to assess the medication’s safety and efficacy in decreasing secondary hyperparathyroidism in juvenile patients with stage 3 and 4 chronic renal disease. In December 2017, the drug’s research will be completed, and it will be commercially available.
Muscle spasms, diarrhea, and nausea, which are commonly linked with secondary hyperparathyroidism therapy, are expected to stifle the global secondary hyperparathyroidism treatment market expansion.
Due to increased research and development of innovative therapies and prospective medicines for secondary hyperparathyroidism, as well as a high incidence of chronic renal disease, North America dominates the global secondary hyperparathyroidism treatment market. In 2014, 118,000 individuals in the United States began treatment for ESRD, and 662,000 were on chronic dialysis, according to the Centers for Disease Control and Prevention (CDC). In addition, Europe is anticipated to be the second-largest revenue contributor in the global secondary hyperparathyroidism treatment market, with considerable growth expected in the coming years. This is due to the introduction of new medicines and therapies to treat secondary hyperparathyroidism, as well as the existence of a large population affected by the condition in this area. The European Commission granted Amgen’s medication etecalcetide marketing authorization in December 2016 for the treatment of secondary hyperparathyroidism in adults with chronic renal disease.
Due to regional firms undertaking clinical studies for the introduction of new medications, Asia Pacific is projected to be the fastest expanding area. Kyowa Hakko Kirin China Pharmaceutical Co., Ltd is conducting a Phase 4 clinical research to assess the safety and efficacy of Cinacalet, its novel lead chemical for the treatment of patients with mild to moderate SHPT. Cinacalet is scheduled to hit the market by April 2019.
Buy Now This Premium Report to Grow your Business: https://www.coherentmarketinsights.com/promo/buynow/1570
Reasons to Purchase this Report
• Current and future of global secondary hyperparathyroidism treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Major companies contributing in the global secondary hyperparathyroidism treatment market are Kyowa Hakko Kirin Co. Ltd., Amgen, Inc., F. Hoffmann-La Roche AG, OPKO Health, AbbVie, Inc., Leo Pharma, Shire, Inc., Deltanoid Pharmaceuticals, Astellas Pharma, Inc., Sanofi SA, and KAI Pharmaceuticals.
To retain their brand reputation and grow their market share, major companies are concentrating on innovation and new product development. Rayaldee was launched by OPKO Health in June 2016 for the treatment of SHPT in individuals with stage 3 or 4 chronic renal disease.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027